T1	p 107 145	vomiting after breast cancer surgery :
T2	p 218 237	Japanese patients .
T3	p 290 322	patient under general anesthesia
T4	p 393 399	nausea
T5	p 404 421	vomiting ( PONV )
T6	p 449 527	patients who undergo mastectomy ( with axillary dissection ) experience PONV .
T7	p 654 684	women who undergo mastectomy .
T8	p 881 925	breast cancer surgery in Japanese patients .
T9	p 1011 1025	Japanese women
T10	p 1691 1807	total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included
T11	p 1811 1822	the study .
T12	p 1834 1863	group comprised 25 patients .
T13	p 2753 2805	Japanese women who underwent breast cancer surgery .
T14	i 20 62	propofol , droperidol , and metoclopramide
T15	i 190 208	placebo-controlled
T16	i 304 322	general anesthesia
T17	i 470 480	mastectomy
T18	i 556 567	propofol at
T19	i 570 581	subhypnotic
T20	i 624 631	placebo
T21	i 754 770	subhypnotic dose
T22	i 774 782	propofol
T23	i 792 846	conventional antiemetics droperidol and metoclopramide
T24	i 984 1002	placebo-controlled
T25	i 1070 1309	IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture . A standard general anesthetic technique , including sevoflurane and air in oxygen
T26	i 2070 2078	propofol
T27	i 2105 2115	droperidol
T28	i 2146 2160	metoclopramide
T29	i 2188 2195	placebo
T30	i 2325 2335	droperidol
T31	i 2342 2350	propofol
T32	i 2355 2365	droperidol
T33	i 2441 2455	metoclopramide
T34	i 2643 2651	propofol
T35	i 2666 2676	droperidol
T36	i 2860 2868	propofol
T37	i 2873 2883	droperidol
T38	i 2898 2936	metoclopramide 0.2 mg/kg and placebo .
T39	o 82 115	postoperative nausea and vomiting
T40	o 393 399	nausea
T41	o 404 412	vomiting
T42	o 415 419	PONV
T43	o 740 748	efficacy
T44	o 870 874	PONV
T45	o 1303 1309	oxygen
T46	o 1549 1574	extrapyramidal symptoms .
T47	o 1942 1962	patient demographics
T48	o 1965 2025	surgery type , or awakening time . The prevalences of PONV 0
T49	o 2240 2258	prevalence of PONV
T50	o 2407 2418	prevalences
T51	o 2422 2426	PONV
T52	o 2501 2524	Extrapyramidal symptoms
T53	o 2825 2829	PONV